Geode Capital Management
ABEO icon

Geode Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Geode Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.42M Buy
1,209,797
+72,670
+6% +$363K ﹤0.01% 2697
2025
Q4 		$5.99M Buy
1,137,127
+9,996
+0.9% +$50.3K ﹤0.01% 2677
2025
Q3 		$5.95M Buy
1,127,131
+21,269
+2% +$135K ﹤0.01% 2694
2025
Q2 		$6.28M Buy
1,105,862
+623,243
+129% +$3.55M ﹤0.01% 2612
2025
Q1 		$2.3M Buy
482,619
+18,892
+4% +$103K ﹤0.01% 2985
2024
Q4 		$2.58M Sell
463,727
-1,590
-0.3% -$9.78K ﹤0.01% 3040
2024
Q3 		$2.94M Buy
465,317
+83,050
+22% +$434K ﹤0.01% 3005
2024
Q2 		$1.62M Buy
382,267
+140,476
+58% +$717K ﹤0.01% 3172
2024
Q1 		$1.75M Buy
241,791
+22,406
+10% +$142K ﹤0.01% 3165
2023
Q4 		$1.1M Buy
219,385
+22,646
+12% +$99.6K ﹤0.01% 3323
2023
Q3 		$829K Buy
196,739
+39,146
+25% +$148K ﹤0.01% 3404
2023
Q2 		$635K Sell
157,593
-24,895
-14% -$87.1K ﹤0.01% 3549
2023
Q1 		$515K Buy
182,488
+142,616
+358% +$373K ﹤0.01% 3633
2022
Q4 		$122K Buy
39,872
+3,935
+11% +$14.7K ﹤0.01% 4320
2022
Q3 		$109K Sell
35,937
-2
-0% -$8 ﹤0.01% 4535
2022
Q2 		$187K Buy
35,939
+2,970
+9% +$15K ﹤0.01% 4304
2022
Q1 		$259K Buy
32,969
+408
+1% +$2.8K ﹤0.01% 4250
2021
Q4 		$274K Sell
32,561
-36
-0.1% -$661 ﹤0.01% 4338
2021
Q3 		$912K Buy
32,597
+6,316
+24% +$202K ﹤0.01% 3729
2021
Q2 		$1.02M Sell
26,281
-18,087
-41% -$738K ﹤0.01% 3584
2021
Q1 		$2.08M Buy
44,368
+2,150
+5% +$118K ﹤0.01% 3236
2020
Q4 		$1.66M Buy
42,218
+4,370
+12% +$149K ﹤0.01% 3176
2020
Q3 		$965K Sell
37,848
-265
-0.7% -$16.7K ﹤0.01% 3227
2020
Q2 		$2.78M Buy
38,113
+2,668
+8% +$184K ﹤0.01% 2666
2020
Q1 		$1.86M Buy
35,445
+15,468
+77% +$1.03M ﹤0.01% 2708
2019
Q4 		$1.63M Buy
19,977
+2,486
+14% +$175K ﹤0.01% 3095
2019
Q3 		$988K Buy
17,491
+685
+4% +$51.3K ﹤0.01% 3241
2019
Q2 		$2.01M Buy
16,806
+1,633
+11% +$274K ﹤0.01% 2949
2019
Q1 		$2.79M Buy
15,173
+1,525
+11% +$273K ﹤0.01% 2649
2018
Q4 		$2.44M Buy
13,648
+273
+2% +$59.5K ﹤0.01% 2657
2018
Q3 		$4.28M Buy
13,375
+1,131
+9% +$401K ﹤0.01% 2446
2018
Q2 		$4.9M Buy
12,244
+896
+8% +$392K ﹤0.01% 2336
2018
Q1 		$4.07M Buy
11,348
+230
+2% +$85.5K ﹤0.01% 2373
2017
Q4 		$4.41M Buy
11,118
+1,140
+11% +$471K ﹤0.01% 2281
2017
Q3 		$4.25M Buy
9,978
+678
+7% +$182K ﹤0.01% 2300
2017
Q2 		$1.49M Buy
9,300
+1,457
+19% +$199K ﹤0.01% 2899
2017
Q1 		$980K Buy
7,843
+184
+2% +$23.7K ﹤0.01% 3031
2016
Q4 		$928K Buy
7,659
+2,858
+60% +$448K ﹤0.01% 3030
2016
Q3 		$720K Buy
4,801
+2,358
+97% +$231K ﹤0.01% 3104
2016
Q2 		$144K Sell
2,443
-377
-13% -$25.8K ﹤0.01% 3691
2016
Q1 		$180 Buy
2,820
+403
+17% +$26.7K ﹤0.01% 3664
2015
Q4 		$202K Buy
2,417
+87
+4% +$8.73K ﹤0.01% 3684
2015
Q3 		$235K Buy
+2,330
New +$309K ﹤0.01% 3616

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management's ABEO Position: Q1 2026 in Review

Geode Capital Management increased its Abeona Therapeutics (ABEO) stake by 6.4% in Q1 2026, buying an estimated $363K and bringing the position to 1,209,797 shares worth $5.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2697.

Geode Capital Management first reported a position in ABEO in Q3 2015 and has held it in 43 quarters since. The position peaked at $6.28M in Q2 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Geode Capital Management held 1,209,797 shares of Abeona Therapeutics worth $5.42M as of Q1 2026.
  • Geode Capital Management bought 72,670 Abeona Therapeutics shares in Q1 2026, an estimated $363K.
  • Abeona Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2697 holding.
  • Geode Capital Management first reported a position in Abeona Therapeutics in Q3 2015 and has held it in 43 quarters since.
  • Geode Capital Management's Abeona Therapeutics position peaked at $6.28M in Q2 2025.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.